Skip to content

US · ATAI · BIOTECHNOLOGY

Atai Beckley Inc. (ATAI) intrinsic value and stock valuation

$7.35as of 2026-11-21 · Mkt cap 2.67B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Atai Beckley Inc. DCF and intrinsic value

InvestorsCraft values ATAI with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ATAI’s statements →

Atai Beckley Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology New York, NY 10119 ataibeckley.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$4.09M
20192025
Net income
-$-660.05M
20192025
Free cash flow
-$-103.58M
20192025
Total equity
$222M+18.4% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$4.09M$310K$310K$230K$20.4M
Operating income-$-99.76M-$-102.69M-$-125.47M-$-144.43M-$-120.33M
Net income-$-660.05M-$-149.27M-$-40.22M-$-152.38M-$-167.81M
EPSd-$-2.91M-$-932.01K-$-253.23K-$-978.55K-$-1.04M
Operating cash flow-$-102.67M-$-82.44M-$-84.12M-$-104.47M-$-63.25M
Capital expenditure-$-900K-$-100K-$-590K-$-1.02M-$-1.13M
Free cash flow-$-103.58M-$-82.53M-$-84.71M-$-105.49M-$-64.37M
Total assets$310.5M$159.4M$293.5M$305.4M$414.2M
Total debt$2.07M$24.7M$19.1M$15.3M$740K
Net debt-$-83.23M$7.2M-$-25.89M-$-175.27M-$-361.52M
Total equity$222M$116.6M$244.3M$265.8M$386M
Cash and short-term investments$256M$62.3M$179.3M$273.1M$362.3M
Income statement
20252024202320222021
Revenue$4.09M$310K$310K$230K$20.4M
Cost of revenue$1.01M$470K$320K$170K$50K
Gross profit$3.08M-$-170K-$-10K$70K$20.3M
Research and development expenses$53.1M$55M$61.9M$74.1M$47.9M
Selling, general and administrative expenses$49.8M$47.5M$63.6M$70.4M$92.8M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$102.8M$102.5M$125.5M$144.5M$140.7M
Cost and expenses$103.9M$103M$125.8M$144.7M$140.7M
Interest income$1.48M$780K$1.85M$550K$200K
Interest expense$1.16M$3.12M$2.66M$920K$0.00
Depreciation and amortization$1.01M$470K$320K$170K$50K
Ebitda-$-657.67M-$-147.33M-$-39.9M-$-150.1M-$-178.19M
Operating income-$-99.76M-$-102.69M-$-125.47M-$-144.43M-$-120.33M
Total other income/expenses, net-$-560.09M-$-48.24M$82.6M-$-6.76M-$-57.91M
Income before tax-$-659.85M-$-150.93M-$-42.88M-$-151.19M-$-178.23M
Income tax expense$300K-$-880K$1.02M$6.23M-$-3.99M
Net income-$-660.05M-$-149.27M-$-40.22M-$-152.38M-$-167.81M
Weighted average shares outstanding$226.5M$160.2M$158.8M$155.7M$160.7M
Weighted average diluted shares outstanding$226.5M$160.2M$158.8M$155.7M$160.7M
Balance sheet
20252024202320222021
Cash and short-term investments$256M$62.3M$179.3M$273.1M$362.3M
Net receivables$14.4M$1.35M$2.26M$5.63M$6.32M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$275.7M$80.1M$185.6M$287.1M$375.1M
Property, plant and equipment, net$4.01M$3.87M$2.2M$1.15M$150K
Goodwill and intangible assets$11.9M$3.58M$1.77M$0.00$0.00
Long-term investments$900K$71M$91.7M$6.75M$27.8M
Total non-current assets$34.9M$79.3M$107.9M$18.3M$39.1M
Total assets$310.5M$159.4M$293.5M$305.4M$414.2M
Accounts payable$4.91M$2.62M$4.59M$2.4M$6M
Short-term debt$270K$9.84M$280K$180K$0.00
Deferred revenue$1.52M$0.00$0.00$0.00$0.00
Total current liabilities$23.5M$25M$20.1M$19.9M$20.9M
Long-term debt$1.8M$14.9M$18.9M$15.2M$740K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$65.1M$17.9M$29M$19.8M$7.27M
Capital lease obligations$1.8M$1.21M$1.26M$220K$0.00
Total liabilities$88.5M$42.8M$49.2M$39.7M$28.2M
Common stock$3.63M$18.8M$18.6M$18.6M$18M
Retained earnings-$-1.36B-$-700.21M-$-550.94M-$-510.19M-$-357.8M
Accumulated other comprehensive income (loss)-$-20.93M-$-18.47M-$-19.46M-$-21.7M-$-8.34M
Total equity$222M$116.6M$244.3M$265.8M$386M
Total investments$171.6M$115.8M$225.9M$89.3M$27.8M
Total debt$2.07M$24.7M$19.1M$15.3M$740K
Net debt-$-83.23M$7.2M-$-25.89M-$-175.27M-$-361.52M
Cash flow statement
20252024202320222021
Net income-$-660.05M-$-150.05M-$-43.9M-$-157.42M-$-174.24M
Depreciation and amortization$1.01M$470K$320K$170K$50K
Stock-based compensation$0.00$25.5M$33M$42.4M$63.4M
Change in working capital-$-6.47M-$-9.2M$7.47M-$-3.33M-$-7.6M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-1.7M-$-1.87M$2.14M-$-3.03M$2.3M
Net cash provided by operating activities-$-102.67M-$-82.44M-$-84.12M-$-104.47M-$-63.25M
Investments in property, plant and equipment-$-10.87M-$-100K-$-260K-$-770K-$-1.13M
Acquisitions, net$4.64M$360K-$-440K$0.00-$-52.94M
Net cash used for investing activities-$-109.13M$59.2M-$-53.3M-$-86.85M-$-81.28M
Common stock issued$283.4M$540K$0.00$0.00$409.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$269.5M$5.37M-$-8.36M$20.8M$409.9M
Net change in cash$57.8M-$-17.53M-$-145.58M-$-171.65M$265M
Cash at end of period$85.3M$27.5M$45M$190.6M$362.3M
Operating cash flow-$-102.67M-$-82.44M-$-84.12M-$-104.47M-$-63.25M
Capital expenditure-$-900K-$-100K-$-590K-$-1.02M-$-1.13M
Free cash flow-$-103.58M-$-82.53M-$-84.71M-$-105.49M-$-64.37M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Atai Beckley Inc.

        Atai Beckley Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the discovery, advancement, and commercialization of innovative therapeutic solutions for a variety of mental health conditions. The company's operations extend across the United States, Germany, and Canada. Its development pipeline features several key compounds: BPL-003: An intranasally administered formulation of mebufotenin benzoate salt, currently undergoing Phase 2a and 2b clinical trials for its potential in treating both treatment-resistant depression (TRD) and alcohol use disorder. RL-007: An orally active, pro-cognitive neuromodulator, progressing through a Phase 2b study focused on cognitive impairment associated with schizophrenia. ELE-101: A serotonergic psychedelic compound designed to address major depressive disorder. VLS-01: An oral transmucosal film featuring N,N-Dimethyltryptamine, which is in a Phase 2 clinical study for TRD. EMP-01: An orally administered form of R-3,4-methylenedioxy-methamphetamine, also in Phase 2 trials for social anxiety disorder. EGX-A & EGX-B: Non-hallucinogenic 5-HT2A receptor agonists, which are being explored for treatment-resistant depression. Beyond these pipeline assets, the firm also provides COMP360 for psilocybin therapy and GRX-917, aimed at treating anxiety, depression, and various neurological conditions. Originally known as Atai Beckley N.V., the entity officially changed its name to Atai Beckley Inc. in December 2025. Established in 2018, its corporate headquarters are situated in New York, New York.

        CEO
        Srinivas G. Rao
        Employees
        99
        Beta
        1.57

        Explore

        Frequently asked questions

        What is the intrinsic value of Atai Beckley Inc. (ATAI)?

        Atai Beckley Inc. (ATAI) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ATAI undervalued?

        ATAI trades at a price of $7.35 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.